Nathalie Adda Biography and Net Worth



Dr. Adda joined Enanta in June 2015. Dr. Adda is a specialist in infectious disease and has more than 20 years of experience in the pharmaceutical industry in all phases of global clinical research and development and commercialization. Most recently, Dr. Adda was Chief Medical Officer, VP Clinical Development, Medical and Regulatory Affairs at Transgene SA, where she led the Oncology and Infectious Disease programs since 2012. From 2006 to 2012, she was Senior Medical Director and the medical lead for the Incivek® (telaprevir) Clinical Program at Vertex Pharmaceuticals Inc., where she designed the phase 2 and Phase 3 programs, and led the medical team in its successful marketing applications and registration in the USA, Canada, and, Asia. Earlier in her career, she held medical and research positions at Gilead, Triangle Pharmaceuticals and Boehringer Ingelheim, where she worked on programs for infectious diseases such as human immunodeficiency virus, hepatitis B virus and hepatitis C virus.

Dr. Adda is a graduate of the University of Paris, where she received a Doctorate in Medicine, as well as a Master’s Degree in Biostatistics, and where she did post-graduate work in infectious diseases.

What is Nathalie Adda's net worth?

The estimated net worth of Nathalie Adda is at least $245,398.73 as of April 1st, 2022. Dr. Adda owns 34,982 shares of Enanta Pharmaceuticals stock worth more than $245,399 as of March 6th. This net worth evaluation does not reflect any other investments that Dr. Adda may own. Learn More about Nathalie Adda's net worth.

How do I contact Nathalie Adda?

The corporate mailing address for Dr. Adda and other Enanta Pharmaceuticals executives is 500 ARSENAL STREET, WATERTOWN MA, 02472. Enanta Pharmaceuticals can also be reached via phone at (617) 607-0800 and via email at cmiceli@enanta.com. Learn More on Nathalie Adda's contact information.

Has Nathalie Adda been buying or selling shares of Enanta Pharmaceuticals?

Nathalie Adda has not been actively trading shares of Enanta Pharmaceuticals during the last ninety days. Most recently, Nathalie Adda sold 32,785 shares of the business's stock in a transaction on Monday, April 4th. The shares were sold at an average price of $72.18, for a transaction totalling $2,366,421.30. Following the completion of the sale, the vice president now directly owns 34,982 shares of the company's stock, valued at $2,525,000.76. Learn More on Nathalie Adda's trading history.

Who are Enanta Pharmaceuticals' active insiders?

Enanta Pharmaceuticals' insider roster includes Nathalie Adda (VP), Jay Luly (CEO), and Paul Mellett, Jr. (Sr. VP of Fin. & Admin. and CFO ). Learn More on Enanta Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Enanta Pharmaceuticals?

During the last year, Enanta Pharmaceuticals insiders bought shares 1 times. They purchased a total of 45,000 shares worth more than $256,050.00. During the last year, insiders at the biotechnology company sold shares 5 times. They sold a total of 24,365 shares worth more than $306,026.21. The most recent insider tranaction occured on February, 12th when CEO Jay R Luly bought 45,000 shares worth more than $256,050.00. Insiders at Enanta Pharmaceuticals own 13.9% of the company. Learn More about insider trades at Enanta Pharmaceuticals.

Information on this page was last updated on 2/12/2025.

Nathalie Adda Insider Trading History at Enanta Pharmaceuticals

See Full Table

Nathalie Adda Buying and Selling Activity at Enanta Pharmaceuticals

This chart shows Nathalie Adda's buying and selling at Enanta Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Enanta Pharmaceuticals Company Overview

Enanta Pharmaceuticals logo
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $7.18
Low: $6.95
High: $7.39

50 Day Range

MA: $6.03
Low: $4.82
High: $8.49

2 Week Range

Now: $7.18
Low: $4.71
High: $17.80

Volume

332,689 shs

Average Volume

529,839 shs

Market Capitalization

$153.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54